Clinical significance of BRAF mutation status in circulating tumor DNA of metastatic melanoma patients at baseline

Experimental Dermatology

Volumn 25, Issue 10, 2016, Pages 783-788

  Knol, Anne C ^a   Vallée, Audrey ^a,b   Herbreteau, Guillaume ^a,b   Nguyen, Jean Michel ^a,c   Varey, Emilie ^a,b   Gaultier, Aurélie ^c   Théoleyre, Sandrine ^a,b   Saint Jean, Mélanie ^a,b   Peuvrel, Lucie ^a,b   Brocard, Anabelle ^a,b   Quéreux, Gaëlle ^a,b   Khammari, Amir ^a,b   Denis, Marc G ^a,b   Dréno, Brigitte ^a,b  

^a Team 12   (France)

^b HÔTEL DIEU   (France)

^c NANTES UNIVERSITY HOSPITAL   (France)

Author keywords

BRAF mutation; metastatic melanoma; overall survival; plasma DNA

Indexed keywords

B RAF KINASE; DNA; LACTATE DEHYDROGENASE; PROTEIN S 100;

ARTICLE; CANCER PROGNOSIS; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; GENE AMPLIFICATION; GENE MUTATION; HUMAN; HUMAN TISSUE; METASTATIC MELANOMA; OVERALL SURVIVAL; TUMOR VOLUME;

EID: 84988914443     PISSN: 09066705     EISSN: 16000625     Source Type: Journal    
DOI: 10.1111/exd.13065     Document Type: Article

References (28)

1. Parkin DM, Bray F, Ferlay J, et al. Int J Cancer. 2001;94:153–156.
2. Vogelstein B, Papadopoulos N, Velculescu VE, et al. Science. 2013;339:1546–1558.
3. Johnson DB, Sosman JA. Curr Treat Options Oncol. 2013;14:280–292.
4. Davies H, Bignell GR, Cox C, et al. Nature. 2002;417:949–954.
5. Arkenau HT, Kefford R, Long GV. Br J Cancer. 2011;104:392–398.
6. Bettegowda C, Sausen M, Leary RJ, et al. Sci Transl Med. 2014;6:224ra224.
7. Fleischhacker M, Schmidt B. Biochim Biophys Acta. 2007;1775:181–232.
8. Goebel G, Zitt M, Zitt M, et al. Dis Markers. 2005;21:105–120.
9. van der Vaart M, Pretorius PJ. Ann N Y Acad Sci. 2008;1137:18–26.
10. Pupilli C, Pinzani P, Salvianti F, et al. J Clin Endocrinol Metab. 2013;98:3359–3365.
11. Daniotti M, Vallacchi V, Rivoltini L, et al. Int J Cancer. 2007;120:2439–2444.
12. Panka DJ, Sullivan RJ, Mier JW. Melanoma Res. 2011;20:401–407.
13. Saint-Jean M, Quereux G, Nguyen JM, et al. Oncol Rep. 2014;32:808–814.
14. Saint-Jean M, Quereux G, Nguyen JM, et al. J Invest Dermatol. 2014;134:1468–1470.
15. Denis MG, Knol AC, Theoleyre S, et al. Clin Chem. 2015;61:886–888.
16. Colombino M, Capone M, Lissia A, et al. J Clin Oncol. 2012;30:2522–2529.
17. Heinzerling L, Baiter M, Kuhnapfel S, et al. Br J Cancer. 2013;109:2833–2841.
18. Shinozaki M, O'Day SJ, Kitago M, et al. Clin Cancer Res. 2007;13:2068–2074.
19. Vallee A, Marcq M, Bizieux A, et al. Lung Cancer. 2013;82:373–374.
20. Sanmamed MF, Fernandez-Landazuri S, Rodriguez C, et al. Clin Chem. 2015;61:297–304.
21. Gray ES, Rizos H, Reid AL, et al. Oncotarget. 2015;6:42008–42018.
22. Couraud S, Vaca-Paniagua F, Villar S, et al. Clin Cancer Res. 2014;20:4613–4624.
23. Jovelet C, Ileana E, Le Deley MC, et al. Clin Cancer Res. 2016 [Epub ahead of print].
24. Balch CM, Gershenwald JE, Soong SJ, et al. J Clin Oncol. 2009;27:6199–6206.
25. Diaz-Lagares A, Alegre E, Arroyo A, et al. Tumour Biol. 2011;32:1155–1161.
26. Sanmamed MF, Fernandez-Landazuri S, Rodriguez C, et al. Clin Chim Acta. 2014;429:168–174.
27. Ashida A, Uhara H, Mikoshiba A, et al. Acta Derm Venereol. 2015;96:128–129.
28. Sundaresan TK, Sequist LV, Heymach JV, et al. Clin Cancer Res. 2016;22:1103–1110.